Archives

Recent

Latest news

| Tuesday, September 15th 2020

Recording of webinar – CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months

Read More
| Friday, September 11th 2020

Registration open for TreatER webcast seminar on 18 November 2020 – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson’s

Read More
| Thursday, August 27th 2020

Renishaw announces completion of clinical trial extension study, using its innovative drug delivery system in the investigation of CDNF as a treatment for Parkinson’s disease

Read More
| Thursday, August 27th 2020

Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months

Read More
| Wednesday, April 15th 2020

Initial clinical data shows promising signals of the biological activity of CDNF in Parkinson’s disease

Read More
| Thursday, March 5th 2020

CDNF early data show biological promise

Read More
| Tuesday, February 25th 2020

Renishaw announces completion of the main part of a multi-centre clinical trial

Read More
| Tuesday, February 25th 2020

Herantis Pharma Plc announces topline results of Phase 1-2 CDNF trial

Read More